CBD and biologics: a research-led safety overview

What the science says

Why biologics aren't on the CBD-interaction lists

Biologics are large-protein therapeutics — most are monoclonal antibodies or recombinant fusion proteins. They're cleared via proteolysis: peptide breakdown by proteases throughout the body. They are not substrates of the liver CYP enzymes that metabolize small-molecule drugs. CBD's CYP3A4, CYP2C9, and CYP2C19 inhibition is therefore irrelevant to biologic clearance. Stöllberger 2023's 403-drug CBD-interaction review reflects this: biologics are not on the list of drugs with CYP overlap.

Why this is counterintuitive

Biologics feel "stronger" than oral pills — the weekly injection, the high cost, the precautions about live vaccines and infections. Patients reasonably assume "stronger drug equals bigger interaction risk." For CYP-pathway interactions specifically, that intuition is wrong. The class of mechanism (small molecule going through liver CYP enzymes) just doesn't apply to antibody-based therapeutics.

What still matters

Biologics suppress immune function in specific ways — TNF-α inhibition (Humira, Enbrel), IL-17 inhibition (Cosentyx, Taltz), IL-23 inhibition (Skyrizi, Stelara, Tremfya), and others. CBD has its own immune-modulating effects: Rodríguez Mesa 2021's systematic review of 24 articles documented Th1/Th17 downregulation across animal models. The clinical relevance of this overlap in humans is unstudied — but it's a question for your prescriber, not a reason to assume the combination is risky.

The mechanism (or absence of one)

A monoclonal antibody is a 150,000-dalton protein. It can't be a substrate of a liver CYP enzyme — that's not how proteases work. When you inject Humira, the adalimumab molecule binds TNF-α in circulation, is internalized by cells, and is degraded into amino acids by intracellular proteases. CBD's effect on CYP3A4 has no point of contact with that pathway.

The same is true for fusion proteins (Enbrel is a TNF-receptor-Fc fusion), pegylated antibody fragments (Cimzia), and recombinant cytokine antagonists across the biologic class. See the CYP450 mechanism explainer for the foundational pharmacology.

What this means for you

1. Talk to your prescriber. Even though CYP-interaction isn't the concern, the immunosuppression context is. Your rheumatologist, dermatologist, or gastroenterologist should know about any addition to your stack.
2. CBD doesn't replace your biologic. Biologics target specific cytokines and modify disease course. CBD has not been shown to do that. Reclaim does not recommend stopping or adjusting biologic therapy.
3. The other drugs in your stack matter more. A common combination is biologic + methotrexate + sometimes prednisone. The CBD-interaction concerns shift to the small-molecule DMARDs — see our methotrexate and prednisone pages.
4. Format choice. Topical CBD (the NANO roll-on) has minimal systemic absorption and is the lowest-systemic-exposure option if your prescriber wants to minimize total CBD exposure. The 50mg patches are isolate-based and drug-test-safe.
5. Watch for liver enzymes. Some biologics (TNF inhibitors especially) require periodic LFT monitoring. CBD at high doses with concomitant valproate has elevated LFTs in clinical populations; at wellness doses (25–50mg/day) the concern is small but not zero.

JAK inhibitors are NOT biologics

Important clarification because JAK inhibitors are frequently conflated with biologics in patient discussions. Rinvoq (upadacitinib), Xeljanz (tofacitinib), and Olumiant (baricitinib) are small-molecule oral drugs — not antibodies. They are metabolized partly by CYP3A4. The CBD-CYP3A4 interaction concern that does not apply to antibody biologics does apply to JAK inhibitors.

The same is true for apremilast (Otezla), an oral PDE4 inhibitor — small molecule, CYP3A4-metabolized, not a biologic despite the autoimmune indication. If you're on a JAK inhibitor or Otezla, the relevant page is the drug-interactions hub and the CYP450 explainer; dedicated per-drug JAK pages are coming in a future build.

Biologic brand-name reference